Company News
CURREBT POSITION:Home >  > Company News

Exclusive Distribution Agreement with Pfizer Inc on Cefobid®


October,2014, Tibet Hemony PharmaCo., Ltd has reached agreement with Pfizer Inc on the product Cefobid® 1.0g ( cefoperazone sodium injection) about Exclusive Distribution Agreement.

Cefoperazone main component of Cefobid®, as the third-generation semi-synthetic broad-spectrum cephalosporin, can antagonize degradation within a variety of β-lactamase, a broad spectrum antibiotic, have effects on gram-positive bacteria and negative bacteria, such as Staphylococcus aureus (including strains produce or not produce penicillinase), Streptococcus pneumoniae, most of the β-hemolytic streptococcus strains of E. coli, Klebsiella spp., production of citric acid species, Haemophilus influenzae, Proteus mirabilis , Proteus, Salmonella and Shigella spp., Pseudomonas aeruginosa, Neisseria gonorrhoeae and Neisseria meningitidis. Patients are used for a variety of infections caused by susceptible strains, such as respiratory infections, peritonitis, cholecystitis, pyelonephritis, urinary tract infections, meningitis, septicemia, bone and joint infections, pelvic inflammatory disease, endometritis, gonorrhea, skin and soft tissue infections. Pseudomonas aeruginosa is more active than other cephalosporin, stable to β- lactamase with the injection method of administration. Treatment of infections caused by Pseudomonas aeruginosa, cefoperazone is one of the most commonly used third-generation cephalosporin, an antibiotic widely used in Chinese medical institutions.


WilCopyright © Tibet Hemony Pharma Co., Ltd. All Rights Reserved [Yu ICP No.10201912-1] Company Add: New Sunshine B2-2-302,NO.158,Jinzhu West Road
Sales center:Jiulongpo District,Secco Garden Two Stree147,No.3-1,Chongqing China Best Regards Support: Han Shake Technology